NextCure (NXTC) Presents At The 19th Annual Morgan Stanley Virtual Global Healthcare Conference - Slideshow

Pipeline Progress - NC318 (S15) monotherapy is in Phase 2 with a data update expected in Q4 2021[13] - NC318 (S15) in combination with anti-PD-1 is in an investigator-initiated trial (IIT) with initial data anticipated in 1H 2022[13] - NC410 (LAIR-1) is in Phase 1 with initial data expected in 2H 2021[13] - NC762 (B7-H4) is in Phase 1 with initial data expected in mid-2022[13] Clinical Trial Updates - NC318 Phase 1 included 49 patients across 15 tumor types, showing 1 confirmed CR in NSCLC (118+ weeks) and 1 confirmed PR in NSCLC (92+ weeks)[20] - NC318 Phase 2 resumed enrollment of NSCLC adenocarcinoma cohort at 800 mg weekly, showing 1 confirmed PR in H&N (40 weeks) and 1 confirmed PR in TNBC (21 weeks)[21] - Yale initiated a Phase 2 trial of NC318 with pembrolizumab in S15+ patients with PD-1 refractory NSCLC in April 2021[26] - NC410 Phase 1 is a dose-escalation study from 3 mg to 400 mg in advanced or metastatic solid tumors, with initial data expected in 4Q 2021[49] - NC762 Phase 1 is a dose-escalation study in advanced or metastatic solid tumors, with initial data expected in mid-2022[55] Financial Position - The company's cash position was $249.5 million as of Q2 2021, providing a runway into 2H 2023[66]